Ved Srivastava, PhD

Ved Srivastava, PhD

Vice President, Head of Chemistry

Ved Srivastava is the Vice President of Chemistry at Aktis Oncology. Ved’s career spans more than 30 years as an expert in peptide medicinal chemistry, formulation and drug delivery, and chemistry manufacturing control (CMC). Prior to his time at Aktis, Ved has served as Vice President of Chemistry at Intarcia Therapeutics, co-founder and Vice President of Peptide Chemistry at Phoundry Pharmaceuticals, and Head of Peptide Chemistry at both GlaxoSmithKline and Amylin Pharmaceuticals. He also has served as a scientific advisory board member to several peptide-based biotech companies. Ved currently serves as Vice Chair and member of the Peptides Expert Committee of the United States Pharmacopeia and in the governance of the American Chemical Society and the American Peptide Society (APS). He served as President of the APS from 2019-2021. Ved’s scientific research interests are in oncology, metabolic diseases, CNS, and inflammation therapeutic areas, and he has significantly contributed to the development of several peptide-based drugs, including ByettaTM, SymlinTM, and BydureonTM. He has co-authored and published numerous peer-reviewed manuscripts, patents, and abstracts and is the editor of five books focused on peptide therapeutics. Ved holds a PhD in organic chemistry from the University of Lucknow, India, and his hobbies include international travel and community service.